Introduction: Temporary non-tunneled catheters are necessary in patients with chronic kidney disease requiring acute hemodialysis care, and complications associated with these catheters, such as infection and thrombosis, represent the most important sources of morbidity. There are no studies available that suggest the optimum duration of their use before catheter exchange or removal. This study aimed to explore the duration of temporary catheter insertion before the occurrence of catheter-related infection and mechanical complications in hemodialysis patients. Methods: Systematic searches were conducted according to the PRISMA 2020 guidelines on four databases up to 1 May 2025 (PROSPERO: CRD420251069657). The study outcome was the occurrence time to catheter-related infection and mechanical complications (thrombosis, obstruction, and kinking, causing dysfunction, failure, or insufficient blood flow) in days, pooled using a single-arm meta-analysis. Mean and 95% confidence interval (CI) were used as the summary statistics. Results: Nine studies involving 1448 participants undergoing hemodialysis using temporary catheters were included. Incidence of infection ranged from 0.7 to 13.58 per 1000 catheter-days. The most common bacterium identified was Staphylococcus aureus and Pseudomonas aeruginosa. The pooled mean time to catheter-related infection from 298 catheters was 15.98 days (95% CI 10.47–21.50; I2 = 97.73%). We also found that the pooled mean time to mechanical complications from 507 catheters was 6.69 days (95% CI 2.49–10.90; I2 = 98.03%). Conclusion: Among patients who developed complications, the mean time from temporary catheter insertion was approximately two weeks to the occurrence of catheter-related infection and one week to mechanical complications. Our finding was consistent with the recommendation of the KDOQI guideline, which suggests limiting catheter duration to typically less than two weeks.
Introduction: Chronic kidney disease represents a significant global health burden, with dialysis as the most prevalent modality for end-stage kidney disease (ESKD) treatment. One of the major causes of ESKD is diabetes mellitus. Diabetic patients undergoing dialysis have higher mortality risk so optimal timing for its initiation is critical in maximizing survival and quality of life. This study aimed to explore the mortality risk of early versus late dialysis initiation in ESKD patients with diabetes. Methods: Systematic searches were conducted according to the PRISMA 2020 guidelines on PubMed, Scopus, ProQuest, and several databases through Web of Science up to 20 May 2025 (PROSPERO CRD420251074686). Effect sizes were presented as hazard ratios (HRs) with 95% confidence intervals (CIs) and 95% prediction intervals (PIs), pooled using a restricted maximum likelihood random-effects model. Subgroup and meta-regression analyses were also performed to search for potential confounding variables. Results: Eight studies involving 303,116 patients were included. Two studies defined early and late dialysis initiation using an estimated glomerular filtration rate (eGFR) cut-off of 5.0 mL/min/1.73 m2, while the remaining studies used cut-offs ranging from 7.0 to 7.7 mL/min/1.73 m2. The pooled hazard ratio (HR) showed no significant difference in the mortality risk between early and late initiation of dialysis in ESKD patients with diabetes mellitus (HR 1.02, 95% CI 0.79–1.31, p = 0.90, I2 = 97.87%, 95% PI 0.45–2.32). Sensitivity analysis showed that the pooled HR was robust. Subgroup analysis demonstrated no significant difference in the pooled HR according to different study designs. Meta-regressions also showed that the year of population sampling, mean age, and follow-up duration of mortality risk did not have significant associations with the pooled HR. Conclusions: Early dialysis initiation does not appear to confer a survival benefit in ESKD patients with diabetes mellitus. However, given the limited and heterogeneous evidence, further high-quality studies are needed. We suggest that dialysis initiation in this specific population should be guided by clinical indications.
About Me
I am internal medicine specialist doctor. Based in Surabaya (now) and Lombok island.
I am internal medicine specialist doctor. Based in Surabaya (now) and Lombok island.